COSCIENS Biopharma Inc. (CSCI) Financials

CSCI

FY2025 annual

Revenue $7.5M -21.8% YoY

Net Income -$10.4M +32.3% YoY

Free Cash Flow -$9.2M +41.6% YoY

Operating Cash Flow -$8.5M +41.8% YoY

Source SEC Filings (10-K/10-Q) Latest period FY2025, ended Dec 31, 2025 Reported Mar 25, 2026 Currency USD FYE December

Newest figures come from the 10-K for FY2025, filed Mar 25, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the CSCI SEC filings page.

COSCIENS Biopharma Inc. (CSCI) reported $7.5M in revenue for fiscal year 2025, down 21.8% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI CSCI FY2025 2026-10-03

Revenue is shrinking while recurring losses and cash outflows remain large, eroding equity and increasing reliance on balance-sheet financing.

Operating cash flow deteriorated sharply in FY2024 before improving in FY2025, but remained negative at -$8.5M. Because FY2025 net income was also a net loss of $10.4M, cash conversion broadly corroborated the accounting loss rather than showing profit converted into cash.

Revenue fell 21.8% from FY2024 to FY2025, but the net loss narrowed 32.3%; losses improved faster than sales, pointing to cost or working-capital changes rather than renewed top-line momentum. The pattern does not describe a volume-led recovery.

Equity fell from $13.2M in FY2024 to $3.8M in FY2025, even as long-term debt declined modestly. The 0.5x debt-to-equity ratio therefore reflects a thinner equity cushion more than a debt surge, while reported liquidity measured 10.3 months of the latest annual operating outflow.

Financial Health Signals

Financial Health Score 34/100

Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of COSCIENS Biopharma Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway

COSCIENS Biopharma Inc. held $7.3M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $8.5M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and COSCIENS Biopharma Inc. scores 30/100 among other emerging companies.

Dilution

COSCIENS Biopharma Inc. had 3M shares outstanding at the end of fiscal year 2025, against 3M in fiscal year 2024. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and COSCIENS Biopharma Inc. scores 80/100 among other emerging companies.

R&D Intensity

Not available for COSCIENS Biopharma Inc., and counted as zero in the overall score.

Revenue Progress

COSCIENS Biopharma Inc. reported revenue of $7.5M in fiscal year 2025, against $9.6M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and COSCIENS Biopharma Inc. scores 46/100 among other emerging companies.

Burn Trend

COSCIENS Biopharma Inc.'s operations used $8.5M of cash in fiscal year 2025, against $14.6M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and COSCIENS Biopharma Inc. scores 10/100 among other emerging companies.

Balance Sheet

COSCIENS Biopharma Inc.'s cash, cash equivalents and investments came to $7.3M at the end of fiscal year 2025, against $17.6M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and COSCIENS Biopharma Inc. scores 40/100 among other emerging companies.

Piotroski F-Score Partial

2/8

COSCIENS Biopharma Inc. passes 2 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.

Earnings Quality No Cash Backing

N/A

COSCIENS Biopharma Inc. reported a net loss of $10.4M while operations used $8.5M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$1.8M

YoY-46.8%

QoQ+19.1%

COSCIENS Biopharma Inc. generated $1.8M in revenue in Q4 2025. This represents a decrease of 46.8% from the same quarter a year earlier. Against the prior quarter it is up 19.1%.

Net Income

-$2.2M

YoY+67.6%

QoQ-20.0%

COSCIENS Biopharma Inc. reported -$2.2M in net income in Q4 2025. This represents an increase of 67.6% from the same quarter a year earlier. Against the prior quarter it is down 20.0%.

EBITDA

Not reported for Q4 2025.

EPS (Diluted)

Not reported for Q4 2025.

Cash & Balance Sheet

Free Cash Flow

-$1.5M

YoY+54.2%

QoQ-122.9%

COSCIENS Biopharma Inc. recorded an outflow of $1.5M in free cash flow in Q4 2025, representing a cash shortfall after capex. This represents an increase of 54.2% from the same quarter a year earlier. Against the prior quarter it is down 122.9%.

Cash & Debt

$7.3M

YoY-55.4%

QoQ-14.3%

5Y CAGR-21.3%

COSCIENS Biopharma Inc. held $7.3M in cash against $1.9M in long-term debt as of Q4 2025.

Shares Outstanding

YoY+1.4%

COSCIENS Biopharma Inc. had 3M shares outstanding in Q4 2025. This represents an increase of 1.4% from the same quarter a year earlier.

Dividends Per Share

Not reported for Q4 2025.

Margins & Returns

Return on Equity

-56.8%

YoY-5.7pp

QoQ-21.0pp

5Y change-46.9pp

COSCIENS Biopharma Inc.'s ROE was -56.8% in Q4 2025, measuring profit generated per dollar of shareholder equity. This is down 5.7 percentage points from the same quarter a year earlier. Against the prior quarter it is down 21.0 percentage points.

Gross Margin

Not reported for Q4 2025.

Operating Margin

Not reported for Q4 2025.

Net Margin

Not shown for Q4 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Capital Allocation

Capital Expenditures

$46K

YoY-85.1%

QoQ+1050.0%

COSCIENS Biopharma Inc. invested $46K in capex in Q4 2025, funding long-term assets and infrastructure. This represents a decrease of 85.1% from the same quarter a year earlier. Against the prior quarter it is up 1050.0%.

R&D Spending

Not reported for Q4 2025.

Share Buybacks

Not reported for Q4 2025.

CSCI Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CSCI quarterly income statement

Metric	FY2510-K	FY2410-K	FY2310-K	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15
Revenue	$7.5M-21.8%	$9.6M+34.2%	$7.1M-51.0%	$14.6M+177.0%	$5.3M+44.0%	$3.7M+586.5%	$532K-98.0%	$26.9M+2812.4%	$923K+1.3%	$911K+67.2%	$545K
Interest Expense	$136K+56.3%	$87K-8.4%	$95K+2275.0%	$4K-42.9%	$7K-63.2%	$19K-71.2%	$66K-94.5%	$1.2M-57.2%	$2.8M-38.0%	$4.5M+129.4%	-$15.3M
Income Tax	$10K-88.1%	$84K+109.5%	-$885K-181.9%	$1.1M+1090.8%	-$109K-127.6%	$395K+310.1%	-$188K-103.4%	$5.5M+256.7%	-$3.5M	$0	$0
Net Income	-$10.4M+32.3%	-$15.3M-339.3%	-$3.5M-201.1%	$3.4M+141.2%	-$8.4M-63.5%	-$5.1M+15.3%	-$6.0M-244.3%	$4.2M+124.9%	-$16.8M+32.7%	-$25.0M+50.2%	-$50.1M
Diluted Shares (Avg)	3M+22.6%	3M+39.7%	2M-0.4%	2M	5M	41M+134.8%	17M+2.7%	17M+13.9%	15M+44.5%	10M	N/A

Metric	Q4'2510-K	Q3'256-K	Q2'256-K	Q1'25	Q4'2410-K	Q3'246-K	Q2'246-K	Q1'24
Revenue	$1.8M-46.8%	$1.5M-20.7%	$2.7M+17.6%	$1.5M-27.1%	$3.3M+98.8%	$1.9M-4.1%	$2.3M+67.9%	$2.1M-3.3%
Interest Expense	$17K+100.8%	$504K+18.3%	-$347K-118.7%	-$38K-3900.0%	-$2.2M-220000.0%	$426K+246.3%	$1.9M+9684.2%	$1K+102.1%
Income Tax	N/A	N/A	$1K+100.2%	N/A	$1.1M	-$112K+47.2%	-$474K-101.7%	-$412K
Net Income	-$2.2M+67.6%	-$1.8M+68.4%	-$2.7M-89.9%	-$3.7M-160.9%	-$6.7M-379.8%	-$5.8M-641.6%	-$1.4M-65.3%	-$1.4M+67.1%
Diluted Shares (Avg)	N/A	3M+2.3%	3M+43.0%	3M+70.2%	N/A	3M+68.1%	2M+20.2%	2M+52.2%

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, EBITDA, EPS (Basic), EPS (Diluted).

CSCI Balance Sheet

CSCI quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15
Total Assets	$21.4M-38.9%	$35.1M+47.7%	$23.7M-14.7%	$27.8M-65.2%	$80.1M+116.5%	$37.0M+85.2%	$20.0M-20.1%	$25.0M+12.7%	$22.2M-29.9%	$31.7M	N/A
Current Assets	$11.5M-52.0%	$24.0M+112.8%	$11.3M	N/A	$70.8M+156.5%	$27.6M+153.1%	$10.9M-32.9%	$16.3M+73.3%	$9.4M-58.8%	$22.7M	N/A
Cash & Equivalents	$7.3M-55.4%	$16.4M+145.5%	$6.7M-34.5%	$10.2M+65.5%	$6.2M-74.6%	$24.3M+209.7%	$7.8M-46.0%	$14.5M+86.5%	$7.8M-64.6%	$22.0M-46.9%	$41.5M
Short-Term Investments	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Inventory	$1.3M-51.4%	$2.7M-32.9%	$4.0M+1650.7%	$229K	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$1.3M-46.5%	$2.4M+712.8%	$290K-60.4%	$732K-44.3%	$1.3M-21.8%	$1.7M+155.5%	$658K+123.8%	$294K+33.0%	$221K-39.5%	$365K	N/A
Long-Term Investments	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	$8.1M-7.8%	$8.8M+9.5%	$8.1M-1.9%	$8.2M-4.7%	$8.6M+14.0%	$7.6M-3.6%	$7.8M
Total Liabilities	$17.6M-19.7%	$21.9M+708.5%	$2.7M-32.6%	$4.0M-85.2%	$27.1M+14.0%	$23.8M+6.0%	$22.4M-2.9%	$23.1M-7.5%	$25.0M-1.8%	$25.4M	N/A
Current Liabilities	$3.6M-50.0%	$7.2M+450.9%	$1.3M	N/A	$7.8M+63.8%	$4.7M-16.2%	$5.7M+1.1%	$5.6M-3.0%	$5.8M+37.2%	$4.2M	N/A
Non-Current Liabilities	$14.0M-4.8%	$14.7M+949.8%	$1.4M	N/A	$19.4M+1.6%	$19.1M+13.5%	$16.8M-4.1%	$17.5M-8.9%	$19.2M-9.6%	$21.2M	N/A
Long-Term Debt	$1.9M-5.1%	$2.0M+45.7%	$1.4M+2052.3%	$65K+109.7%	$31K-36.7%	$49K-80.8%	$255K	N/A	N/A	N/A	N/A
Total Equity	$3.8M-70.8%	$13.2M-37.4%	$21.0M-11.7%	$23.8M-55.0%	$53.0M+301.1%	$13.2M+636.4%	-$2.5M-229.2%	$1.9M+168.5%	-$2.8M-144.8%	$6.2M-71.3%	$21.6M
Retained Earnings	-$20.5M-69.3%	-$12.1M-378.0%	$4.4M+101.2%	-$352.1M-5.2%	-$334.6M-3.7%	-$322.7M-1.8%	-$316.9M-2.3%	-$309.8M+1.4%	-$314.2M-5.4%	-$298.1M	N/A

Metric	Q4'2510-K	Q3'256-K	Q2'256-K	Q1'25	Q4'2410-K	Q3'246-K	Q2'246-K	Q1'24
Total Assets	$21.4M-38.9%	$23.9M-45.5%	$27.6M-44.9%	$31.1M-2.0%	$35.1M+47.7%	$43.8M+3.0%	$50.0M+7.7%	$31.8M-38.0%
Current Assets	$11.5M-52.0%	$13.8M-51.0%	$16.5M-50.3%	$20.4M-34.8%	$24.0M+112.8%	$28.2M-32.7%	$33.2M-27.6%	$31.2M-38.5%
Cash & Equivalents	$7.3M-55.4%	$8.5M-57.4%	$9.3M-66.4%	$13.8M+292.4%	$16.4M+145.5%	$20.0M+139.1%	$27.8M+225.7%	$3.5M-62.3%
Inventory	$1.3M-51.4%	$1.8M-46.8%	$1.8M-40.4%	$2.5M+3735.9%	$2.7M-32.9%	$3.3M	$3.1M	$64K
Accounts Receivable	$1.3M-46.5%	$1.6M-15.2%	$2.8M+124.8%	$1.9M+878.4%	$2.4M+712.8%	$1.9M+246.5%	$1.2M+569.2%	$190K-65.9%
Total Liabilities	$17.6M-19.7%	$18.8M-20.9%	$20.5M-14.1%	$21.0M+11.6%	$21.9M+708.5%	$23.8M+46.6%	$23.8M+36.9%	$18.8M-6.2%
Current Liabilities	$3.6M-50.0%	$4.0M-51.2%	$5.5M-44.1%	$7.1M+34.4%	$7.2M+450.9%	$8.2M+93.2%	$9.9M+142.8%	$5.3M-18.4%
Non-Current Liabilities	$14.0M-4.8%	$14.8M-5.1%	$14.9M+7.2%	$13.9M+2.7%	$14.7M+949.8%	$15.6M+30.1%	$13.9M+4.4%	$13.6M-0.5%
Long-Term Debt	$1.9M-5.1%	$2.0M+61.8%	$2.0M+60.1%	$2.0M+2366.3%	$2.0M+45.7%	$1.2M+1630.0%	$1.3M+1405.9%	$80K+5.3%
Total Equity	$3.8M-70.8%	$5.1M-74.6%	$7.1M-72.9%	$10.1M-47.1%	$13.2M-37.4%	$20.0M-9.3%	$26.2M+12.2%	$19.2M-38.5%
Retained Earnings	-$20.5M-69.3%	-$19.0M-269.3%	-$17.2M-1223.7%	-$14.7M+96.1%	-$12.1M-378.0%	-$5.2M+98.6%	$1.5M+100.4%	-$375.3M-5.3%

Not reported in any period shown, so not listed: Short-Term Investments, Long-Term Investments, Goodwill.

CSCI Cash Flow Statement

CSCI quarterly cash flow statement

Metric	FY2510-K	FY2410-K	FY2310-K	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15
Operating Cash Flow	-$8.5M+41.8%	-$14.6M-464.2%	-$2.6M-149.4%	$5.2M+160.9%	-$8.6M-107.8%	-$4.1M+61.5%	-$10.7M-257.1%	$6.8M+129.8%	-$22.9M+21.0%	-$29.0M+14.3%	-$33.8M
Depreciation & Amortization	$1.2M-26.1%	$1.6M+11.4%	$1.4M-1.7%	$1.5M+912.4%	$145K-37.5%	$232K-26.3%	$315K+443.1%	$58K-38.3%	$94K-66.4%	$280K-17.9%	$341K
Capital Expenditures	$706K-39.2%	$1.2M+60.8%	$722K+137.5%	$304K+913.3%	$30K	N/A	N/A	$9K+125.0%	$4K-93.9%	$66K+153.8%	$26K
Free Cash Flow	-$9.2M+41.6%	-$15.7M-376.1%	-$3.3M-167.1%	$4.9M+157.2%	-$8.6M	N/A	N/A	$6.8M+129.7%	-$22.9M+21.2%	-$29.1M+14.2%	-$33.9M
Investing Cash Flow	-$458K-101.8%	$25.1M+3536.0%	-$730K-140.1%	-$304K+53.8%	-$658K-1275.0%	$56K+12.0%	$50K+242.9%	-$35K-111.4%	$307K+197.8%	-$314K-134.4%	$913K
Financing Cash Flow	-$407K+30.8%	-$588K-64.7%	-$357K-33.7%	-$267K-100.5%	$51.0M+149.4%	$20.5M+425.8%	$3.9M	$0-100.0%	$8.0M-19.1%	$9.9M-75.7%	$40.8M

Metric	Q4'2510-K	Q3'256-K	Q2'256-K	Q1'25	Q4'2410-K	Q3'246-K	Q2'246-K	Q1'24
Operating Cash Flow	-$1.5M+51.0%	-$676K+91.3%	-$4.4M-220.2%	-$1.9M+21.0%	-$3.0M-176.4%	-$7.8M-5502.1%	-$1.4M-70.8%	-$2.4M+41.4%
Depreciation & Amortization	$289K-26.3%	$287K-40.1%	$287K-23.9%	$325K-9.5%	$392K-42.2%	$479K+32.0%	$377K+4.1%	$359K+797.5%
Capital Expenditures	$46K-85.1%	-$4K-96.9%	$49K-68.8%	$615K+9.0%	$309K-47.4%	$131K+162.0%	$157K+190.7%	$564K+28100.0%
Free Cash Flow	-$1.5M+54.2%	-$680K+91.4%	-$4.5M-190.8%	-$2.5M+15.3%	-$3.3M-97.8%	-$7.9M-8514.9%	-$1.5M-78.3%	-$2.9M+27.5%
Investing Cash Flow	$201K+163.6%	$4K-95.2%	-$48K-100.2%	-$615K-9.0%	-$316K+46.9%	$83K+266.0%	$25.9M+48025.9%	-$564K-28100.0%
Financing Cash Flow	-$15K+92.6%	-$85K+54.8%	-$107K+15.1%	-$200K-112.8%	-$202K-22.4%	-$188K-218.6%	-$126K-80.0%	-$94K-147.4%

Not reported in any period shown, so not listed: Stock-Based Compensation, Dividends Paid, Share Buybacks.

CSCI Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CSCI quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15
Net Margin	-138.1%	-159.7%	-48.8%-72.5pp	23.7%	-159.1%	-140.1%	-1135.7%	15.6%	-1819.7%	-2739.7%	-9200.5%
Return on Equity	-269.6%-153.3pp	-116.3%-99.8pp	-16.6%-31.0pp	14.5%+30.3pp	-15.8%+22.9pp	-38.7%	N/A	219.6%	N/A	-401.8%-169.8pp	-232.0%
Return on Assets	-48.3%-4.7pp	-43.6%-29.0pp	-14.7%-27.1pp	12.4%+22.8pp	-10.4%+3.4pp	-13.8%+16.4pp	-30.2%-47.0pp	16.7%+92.4pp	-75.7%+3.2pp	-78.8%	N/A
Current Ratio	3.18-0.1x	3.32-5.3x	8.59	N/A	9.12+3.3x	5.82+3.9x	1.93-1.0x	2.90+1.3x	1.63-3.8x	5.41	N/A
Debt-to-Equity	0.50+0.3x	0.15+0.1x	0.07+0.1x	0.000.0x	0.000.0x	0.00	N/A	12.12	N/A	4.10	N/A
Asset Turnover	0.35+0.1x	0.270.0x	0.30-0.2x	0.52+0.5x	0.070.0x	0.10+0.1x	0.03-1.0x	1.07+1.0x	0.040.0x	0.03	N/A
FCF Margin	-122.4%	-164.1%	-46.3%-80.1pp	33.8%	-163.7%	N/A	N/A	25.4%	-2482.9%	-3191.7%	-6214.7%

Metric	Q4'2510-K	Q3'256-K	Q2'256-K	Q1'25	Q4'2410-K	Q3'246-K	Q2'246-K	Q1'24
Net Margin	-123.6%	-122.7%	-98.3%-37.4pp	-243.7%	-202.6%	-307.6%	-60.9%+0.9pp	-68.1%
Return on Equity	-56.8%-5.7pp	-35.8%-7.1pp	-38.1%-32.6pp	-36.0%-28.7pp	-51.1%-62.6pp	-28.7%-25.2pp	-5.4%-1.7pp	-7.3%+6.3pp
Return on Assets	-10.2%+9.0pp	-7.6%+5.5pp	-9.8%-7.0pp	-11.7%-7.3pp	-19.2%-29.3pp	-13.2%-11.3pp	-2.8%-1.0pp	-4.4%+3.9pp
Current Ratio	3.18-0.1x	3.470.0x	2.98-0.4x	2.88-3.1x	3.32-5.3x	3.46-6.5x	3.35-7.9x	5.94-1.9x
Debt-to-Equity	0.50+0.3x	0.39+0.3x	0.29+0.2x	0.19+0.2x	0.15+0.1x	0.06+0.1x	0.050.0x	0.000.0x
Asset Turnover	0.080.0x	0.060.0x	0.10+0.1x	0.050.0x	0.090.0x	0.040.0x	0.050.0x	0.060.0x
FCF Margin	-85.8%+13.7pp	-45.9%	-163.5%	-166.3%	-99.6%	-422.8%	-66.1%-3.9pp	-143.1%

Not reported in any period shown, so not listed: Gross Margin, Operating Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Net Margin, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
COSCIENS Biopharma Inc. CSCI	FY2025	$7.5M	-$10.4M	N/A	$8.6M	34/100
AEON Biopharma, Inc. AEON	FY2025	N/A	N/A	N/A	$11.4M	—
Creative Medical Technology Holdings, Inc. CELZ	FY2025	$6K	-$6.0M	N/A	$5.9M	—
Cyclerion Therapeutics, Inc. CYCN	FY2025	$2.1M	-$3.5M	N/A	$19.9M	59/100
Impact BioMedical, Inc. IBO	FY2025	$32K	-$11.8M	N/A	$29.1M	—

Where COSCIENS Biopharma Inc. Ranks

Frequently Asked Questions

What is COSCIENS Biopharma Inc.'s annual revenue?

COSCIENS Biopharma Inc. (CSCI) reported $7.5M in total revenue for fiscal year 2025. This represents a -21.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is COSCIENS Biopharma Inc.'s revenue growing?

COSCIENS Biopharma Inc. (CSCI) revenue declined by 21.8% year-over-year, from $9.6M to $7.5M in fiscal year 2025.

Is COSCIENS Biopharma Inc. profitable?

No, COSCIENS Biopharma Inc. (CSCI) reported a net income of -$10.4M in fiscal year 2025.

How much debt does COSCIENS Biopharma Inc. have?

As of fiscal year 2025, COSCIENS Biopharma Inc. (CSCI) had $7.3M in cash and equivalents against $1.9M in long-term debt.

What is COSCIENS Biopharma Inc.'s return on equity (ROE)?

COSCIENS Biopharma Inc. (CSCI) has a return on equity of -269.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is COSCIENS Biopharma Inc.'s free cash flow?

COSCIENS Biopharma Inc. (CSCI) recorded an outflow of $9.2M in free cash flow during fiscal year 2025. This represents a 41.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is COSCIENS Biopharma Inc.'s operating cash flow?

COSCIENS Biopharma Inc. (CSCI) recorded an outflow of $8.5M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are COSCIENS Biopharma Inc.'s total assets?

COSCIENS Biopharma Inc. (CSCI) had $21.4M in total assets as of fiscal year 2025, including both current and long-term assets.

What are COSCIENS Biopharma Inc.'s capital expenditures?

COSCIENS Biopharma Inc. (CSCI) invested $706K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How many shares does COSCIENS Biopharma Inc. have outstanding?

COSCIENS Biopharma Inc. (CSCI) had 3M shares outstanding as of fiscal year 2025.

What is COSCIENS Biopharma Inc.'s current ratio?

COSCIENS Biopharma Inc. (CSCI) had a current ratio of 3.18 as of fiscal year 2025, which is generally considered healthy.

What is COSCIENS Biopharma Inc.'s debt-to-equity ratio?

COSCIENS Biopharma Inc. (CSCI) had a debt-to-equity ratio of 0.50 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is COSCIENS Biopharma Inc.'s return on assets (ROA)?

COSCIENS Biopharma Inc. (CSCI) had a return on assets of -48.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

How does COSCIENS Biopharma Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, COSCIENS Biopharma Inc. (CSCI) held $7.3M in cash, cash equivalents and investments, and reported an operating cash outflow of $8.5M over that year. Dividing the one by the other, the reported balance equals about 10 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is COSCIENS Biopharma Inc.'s Piotroski F-Score?

COSCIENS Biopharma Inc. (CSCI) has a Piotroski F-Score of 2 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are COSCIENS Biopharma Inc.'s earnings high quality?

COSCIENS Biopharma Inc. (CSCI) reported a net loss of $10.4M while operations used $8.5M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is COSCIENS Biopharma Inc.?

COSCIENS Biopharma Inc. (CSCI) scores 34 out of 100 on our Financial Health Score, indicating weak standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.